Top Infectious Disease News Stories: Week of April 12–18, 2024

This week brought significant developments in global infectious disease surveillance, treatment advances, and public health preparedness. From emerging variants to vaccine updates and antimicrobial resistance concerns, here are the most consequential stories shaping the landscape of infectious disease control.

WHO Monitors New SARS-CoV-2 Variant KP.2 Amid Rising Cases

The World Health Organization (WHO) is closely tracking a new SARS-CoV-2 variant, designated KP.2, which has shown increased transmissibility in early genomic surveillance data. First detected in India in late March, KP.2 carries mutations in the spike protein that may enhance immune evasion, particularly against antibodies generated by prior infection or older vaccine formulations.

As of mid-April, KP.2 accounted for approximately 15% of sequenced cases in India and has been detected in travelers to the United States, the United Kingdom, and Singapore. While current evidence does not suggest increased severity, WHO officials emphasized the importance of continued monitoring and urged high-risk populations to stay up to date with COVID-19 vaccinations.

World Health Organization continues to classify KP.2 as a Variant Under Monitoring (VUM), with weekly risk assessments published through its Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE).

FDA Approves First RSV Vaccine for Adults Aged 18–59 with Chronic Conditions

In a landmark decision, the U.S. Food and Drug Administration (FDA) approved Arexvy (GSK) for use in adults aged 18 to 59 who are at increased risk of severe respiratory syncytial virus (RSV) disease due to underlying chronic medical conditions such as heart or lung disease, diabetes, or immunosuppression.

Previously approved only for adults 60 and older, this expansion follows positive results from a Phase 3 trial showing 83.7% efficacy against severe RSV-associated lower respiratory tract disease in the younger, high-risk cohort. The vaccine, administered as a single intramuscular dose, works by stimulating an immune response against the RSV fusion (F) protein.

The Centers for Disease Control and Prevention (CDC) is expected to issue updated guidance in the coming weeks regarding use of RSV vaccines in younger adults with comorbidities. Healthcare providers are advised to consult CDC’s RSV vaccination page for the latest recommendations.

Global Rise in Drug-Resistant Fungal Infections Prompts CDC Alert

The Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory warning of a sharp increase in invasive infections caused by Candida auris, a multidrug-resistant yeast that poses a serious threat in healthcare settings. Between January and March 2024, reported cases rose by 40% compared to the same period in 2023, with clusters identified in long-term care facilities and intensive care units across New York, Illinois, and California.

C. Auris is particularly concerning due to its resistance to multiple antifungal classes, including azoles, polyenes, and echinocandins, and its ability to persist on surfaces for weeks. The CDC stressed the importance of strict infection control measures, including hand hygiene, environmental disinfection with EPA-registered products effective against C. Auris, and screening of high-risk patients.

Laboratories are urged to use specialized identification methods, as standard biochemical tests may misidentify the organism. More information is available via the CDC’s Candida auris resource page.

Progress Reported in Malaria Vaccine Rollout Across Africa

The World Health Organization reported that over 2 million children in Ghana, Kenya, and Malawi have received at least one dose of the RTS,S/AS01 (Mosquirix) malaria vaccine since the pilot program began in 2019. Recent data show a 30% reduction in severe malaria hospitalizations among vaccinated children, reinforcing the vaccine’s role as a complementary tool alongside insecticide-treated nets and seasonal chemoprevention.

Building on this success, WHO recommended in October 2023 the broader use of a second malaria vaccine, R21/Matrix-M, which demonstrated up to 77% efficacy in Phase 2b trials. The first countries to approve R21/Matrix-M for widespread use include Burkina Faso, Ghana, and Nigeria, with initial shipments expected in mid-2024.

These advances mark a turning point in malaria control, particularly in sub-Saharan Africa, where the disease remains a leading cause of childhood mortality. For ongoing updates, refer to the WHO malaria fact sheet.

Antibiotic Stewardship Gains Traction in U.S. Hospitals

A new analysis published in Clinical Infectious Diseases found that hospitals participating in the CDC’s National Healthcare Safety Network (NHSN) Antibiotic Use Option reported a 12% decline in overall antibiotic days of therapy between 2020 and 2023. The reduction was most pronounced in broad-spectrum agents such as fluoroquinolones and carbapenems, suggesting improved adherence to stewardship principles.

Experts attribute the trend to widespread implementation of antibiotic time-outs, prospective audit and feedback programs, and rapid diagnostic testing that enables quicker de-escalation of therapy. Despite progress, gaps remain in outpatient and long-term care settings, where antibiotic prescribing rates remain high.

The CDC continues to promote antibiotic stewardship through its Be Antibiotics Aware initiative, offering toolkits and training resources for clinicians across care settings.

Looking Ahead: Preparedness for the Next Threat

This week’s developments underscore a dual reality in infectious disease: we are making meaningful progress in prevention and treatment, yet new challenges continue to emerge. Variant surveillance, vaccine equity, antifungal resistance, and antimicrobial stewardship remain critical pillars of global health security.

As we move into late spring and summer, public health officials urge vigilance—not only for respiratory viruses like SARS-CoV-2 and RSV, but too for vector-borne threats such as dengue and West Nile virus, which typically see increased activity with warmer temperatures.

Staying informed through trusted sources like the WHO, CDC, and peer-reviewed journals remains the best defense against misinformation and a key step in protecting individual and community health.

Frequently Asked Questions

Is the KP.2 variant more dangerous than previous SARS-CoV-2 strains?

There is currently no evidence that KP.2 causes more severe illness. However, it may spread more easily and partially evade immunity from prior infection or vaccination. Vaccines still offer strong protection against severe disease.

Who should obtain the newly approved RSV vaccine for adults under 60?

The FDA approved Arexvy for adults aged 18–59 with chronic heart, lung, or metabolic conditions that increase the risk of severe RSV infection. Consult your healthcare provider to determine if you qualify.

How can I protect myself from Candida auris?

For the general public, risk is low. In healthcare settings, strict adherence to infection control practices—including hand hygiene and proper disinfection—is the most effective prevention strategy.

Is the malaria vaccine available in the United States?

No. Malaria vaccines like RTS,S and R21/Matrix-M are currently recommended only for use in children living in moderate-to-high transmission regions of sub-Saharan Africa.

What can I do to facilitate combat antibiotic resistance?

Only take antibiotics when prescribed, complete the full course as directed, never share or use leftover prescriptions, and practice good hygiene to prevent infections in the first place.

Stay updated with evidence-based infectious disease news. Bookmark this page and check back weekly for the latest developments in global health.